Dimerix Ltd

DXB

Company Profile

  • Business description

    Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.

  • Contact

    425 Smith Street
    FitzroyVIC3065
    AUS

    T: +61 1300813321

    https://www.dimerix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.6048.70-0.53%
CAC 407,849.1322.89-0.29%
DAX 4023,576.3934.94-0.15%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,208.0315.29-0.17%
HKSE26,518.65359.531.37%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,630.31136.650.30%
NZX 50 Index13,181.3144.770.34%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,764.5050.50-0.57%
SSE Composite Index3,853.6431.810.83%

Market Movers